Allogene Therapeutics (ALLO) Long-Term Investments: 2019-2025
Historic Long-Term Investments for Allogene Therapeutics (ALLO) over the last 7 years, with Sep 2025 value amounting to $24.9 million.
- Allogene Therapeutics' Long-Term Investments fell 77.69% to $24.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $24.9 million, marking a year-over-year decrease of 77.69%. This contributed to the annual value of $80.7 million for FY2024, which is 2113.25% up from last year.
- As of Q3 2025, Allogene Therapeutics' Long-Term Investments stood at $24.9 million, which was down 15.47% from $29.5 million recorded in Q2 2025.
- In the past 5 years, Allogene Therapeutics' Long-Term Investments registered a high of $378.2 million during Q3 2021, and its lowest value of $1.1 million during Q2 2024.
- In the last 3 years, Allogene Therapeutics' Long-Term Investments had a median value of $32.2 million in 2023 and averaged $40.7 million.
- Per our database at Business Quant, Allogene Therapeutics' Long-Term Investments crashed by 97.84% in 2024 and then soared by 2,502.29% in 2025.
- Allogene Therapeutics' Long-Term Investments (Quarterly) stood at $352.2 million in 2021, then slumped by 83.20% to $59.2 million in 2022, then crashed by 93.84% to $3.6 million in 2023, then spiked by 2,113.25% to $80.7 million in 2024, then crashed by 77.69% to $24.9 million in 2025.
- Its last three reported values are $24.9 million in Q3 2025, $29.5 million for Q2 2025, and $55.5 million during Q1 2025.